Menu

The Precision Medicine Revolution: CRISPR-Based Therapies

The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps for those looking to adopt the technique. 

Sep 7, 2017
The Scientist Creative Services Team

The Precision Medicine Revolution: CRISPR-Based Therapies from thescientistllc on Vimeo.

CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) gene-editing technology has been hailed as a breakthrough and emerged as the new face of precision medicine. Its potential as a treatment for numerous diseases, stretching from various cancer types to neurological diseases to lethal heritable disorders, has been well documented. However, efforts are ongoing that aim to clarify the complex issues surrounding the legality and ethics of genome editing for human use. For a detailed look at the progress made toward CRISPR-mediated correction of human diseases and the continuing ethics debate, The Scientist is bringing together a panel of experts who will share their research, summarize the state of the science, and discuss the next steps for those looking to adopt the technique. Attendees will have the opportunity to interact with experts, ask questions, and seek advice on topics related to their research.

Topics to be covered:

  • CRISPR-generated model systems for in vivo study of a wide range of diseases
  • Therapeutic applications of genome editing and their associated societal implications

Register Now

Meet the Speakers:

Dana Carroll, PhD
Distinguished Professor, Department of Biochemistry
University of Utah School of Medicine

 

 

James Dahlman, PhD
Assistant Professor, Department of Biomedical Engineering
Georgia Institute of Technology and Emory School of Medicine

 

 




 
 

 

 

February 2019

Big Storms Brewing

Can forests weather more major hurricanes?

Marketplace

Sponsored Product Updates

Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Releases First FDA-Cleared Digital PCR System and Test for Monitoring Chronic Myeloid Leukemia Treatment Response
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced that its QXDx AutoDG ddPCR System, which uses Bio-Rad’s Droplet Digital PCR technology, and the QXDx BCR-ABL %IS Kit are the industry’s first digital PCR products to receive U.S. Food and Drug Administration (FDA) clearance. Used together, Bio-Rad’s system and kit can precisely and reproducibly monitor molecular response to treatment in patients with chronic myeloid leukemia (CML).
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Showcases New Automation Features of its ZE5 Cell Analyzer at SLAS 2019
Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) today showcases new automation features of its ZE5 Cell Analyzer during the Society for Laboratory Automation and Screening 2019 International Conference and Exhibition (SLAS) in Washington, D.C., February 2–6. These capabilities enable the ZE5 to be used for high-throughput flow cytometry in biomarker discovery and phenotypic screening.
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Andrew Alliance and Sartorius Collaborate to Provide Software-Connected Pipettes for Life Science Research
Researchers to benefit from an innovative software-connected pipetting system, bringing improved reproducibility and traceability of experiments to life-science laboratories.
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Life Sciences to Feature 3D Cell Culture Technologies at SLAS 2019
Corning Incorporated (NYSE: GLW) will showcase advanced 3D cell culture technologies and workflow solutions for spheroids, organoids, tissue models, and applications including ADME/toxicology at the Society for Laboratory Automation and Screening (SLAS) conference, Feb. 2-6 in Washington, D.C.